Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

(... Continued) Study or subgroup AL Control Risk Ratio Risk Ratio n/N n/N M-H,Random,95% CI M-H,Random,95% CI Subtotal (95% CI) 777 952 1.71 [ 0.97, 3.02 ] Total events: 30 (AL), 18 (Control) Heterogeneity: Tau 2 = 0.0; Chi 2 = 2.16, df = 4 (P = 0.71); I 2 =0.0% Test for overall effect: Z = 1.84 (P = 0.066) 4 Day 42: AL vs Artesunate plus sulfadoxine-pyrimethamine Karunajeewa 2007 PNG 5/74 17/84 0.33 [ 0.13, 0.86 ] Subtotal (95% CI) 74 84 0.33 [ 0.13, 0.86 ] Total events: 5 (AL), 17 (Control) Heterogeneity: not applicable Test for overall effect: Z = 2.27 (P = 0.023) 5 Day 28: AL vs Amodiaquine plus sulfadoxine-pyrimethamine Faye 2003 SEN 0/147 0/154 0.0 [ 0.0, 0.0 ] Fanello 2004 RWA 8/218 51/209 0.15 [ 0.07, 0.31 ] Zongo 2005 BFA 4/212 1/223 4.21 [ 0.47, 37.34 ] Dorsey 2006 UGA 0/95 16/96 0.03 [ 0.00, 0.50 ] Zongo 2007 BFA 6/148 7/167 0.97 [ 0.33, 2.81 ] Subtotal (95% CI) 820 849 0.40 [ 0.08, 2.11 ] Total events: 18 (AL), 75 (Control) Heterogeneity: Tau 2 = 2.11; Chi 2 = 16.71, df = 3 (P = 0.00081); I 2 =82% Test for overall effect: Z = 1.07 (P = 0.28) Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 0.002 0.1 1 10 500 Favours AL Favours Control 214
Analysis 21.1. Comparison 21 How does Artesunate plus amodiaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted. Review: Artemisinin-based combination therapy for treating uncomplicated malaria Comparison: 21 How does Artesunate plus amodiaquine perform? Outcome: 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Study or subgroup ASAQ Control Risk Ratio Risk Ratio 1 Day 28: AS+AQ vs Dihydroartemisinin-piperaquine n/N n/N M-H,Random,95% CI M-H,Random,95% CI Karema 2004 RWA 16/222 10/236 1.70 [ 0.79, 3.67 ] Hasugian 2005 IDN 6/81 1/90 6.67 [ 0.82, 54.20 ] Subtotal (95% CI) 303 326 2.36 [ 0.74, 7.54 ] Total events: 22 (ASAQ), 11 (Control) Heterogeneity: Tau 2 = 0.31; Chi 2 = 1.47, df = 1 (P = 0.22); I 2 =32% Test for overall effect: Z = 1.46 (P = 0.15) 2 Day 28: AS+AQ vs Artesunate plus mefloquine Faye 2003 SEN 0/340 0/142 0.0 [ 0.0, 0.0 ] Subtotal (95% CI) 340 142 0.0 [ 0.0, 0.0 ] Total events: 0 (ASAQ), 0 (Control) Heterogeneity: not applicable Test for overall effect: Z = 0.0 (P < 0.00001) 3 Day 28: AS+AQ vs Artemether-lumefantrine Faye 2003 SEN 0/340 0/147 0.0 [ 0.0, 0.0 ] Guthmann 2004 AGO 0/60 0/59 0.0 [ 0.0, 0.0 ] Falade 2005 NGA 0/56 0/59 0.0 [ 0.0, 0.0 ] Bukirwa 2005 UGA 0/68 2/102 0.30 [ 0.01, 6.12 ] Dorsey 2006 UGA 2/100 0/95 4.75 [ 0.23, 97.72 ] Adjei 2006 GHA 2/104 4/101 0.49 [ 0.09, 2.59 ] Owusu-Agyei 2006 GHA 7/136 12/122 0.52 [ 0.21, 1.29 ] Kobbe 2007 GHA 7/88 12/92 0.61 [ 0.25, 1.48 ] Subtotal (95% CI) 952 777 0.59 [ 0.33, 1.03 ] Total events: 18 (ASAQ), 30 (Control) Heterogeneity: Tau 2 = 0.0; Chi 2 = 2.16, df = 4 (P = 0.71); I 2 =0.0% Test for overall effect: Z = 1.84 (P = 0.066) 4 Day 28: AS+AQ vs Artesunate plus sulfadoxine-pyrimethamine Hamour 2003 SDN 4/55 5/57 0.83 [ 0.23, 2.93 ] Guthmann 2003 AGO 1/79 1/82 1.04 [ 0.07, 16.31 ] Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 0.005 0.1 1 10 200 Favours ASAQ Favours Control (Continued ...) 215
Page 1 and 2:
Artemisinin-based combination thera
Page 3 and 4:
Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6:
Analysis 10.5. Comparison 10 Arteme
Page 7 and 8:
[Intervention Review] Artemisinin-b
Page 9 and 10:
B A C K G R O U N D Malaria is a di
Page 11 and 12:
drugs and the treatment comparisons
Page 13 and 14:
this analysis into participants who
Page 15 and 16:
Figure 1. Methodological quality su
Page 17 and 18:
confidence intervals of the estimat
Page 19 and 20:
Anaemia Hasugian 2005 IDN found tha
Page 21 and 22:
Three trials report significantly m
Page 23 and 24:
or those treated for P. vivax at ba
Page 25 and 26:
Early vomiting Not reported. D I S
Page 27 and 28:
Figure 4. Olliaro-Vaillant plot. Da
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Figure 10. Olliaro-Vaillant plot. D
Page 35 and 36:
of findings tables’. For these ta
Page 37 and 38:
Huambo and Bie provinces, central A
Page 39 and 40:
References to studies excluded from
Page 41 and 42:
Adjuik 2004 Adjuik M, Babiker A, Ga
Page 43 and 44:
C H A R A C T E R I S T I C S O F S
Page 45 and 46:
Ashley 2003a THA (Continued) Outcom
Page 47 and 48:
Ashley 2003b THA (Continued) Alloca
Page 49 and 50:
Ashley 2005 THA (Continued) Exclusi
Page 51 and 52:
Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54:
Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56:
Djimde 2004 MLI (Continued) • AS
Page 57 and 58:
Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60:
Fanello 2004 RWA Methods Trial desi
Page 61 and 62:
Faye 2003 SEN (Continued) Outcomes
Page 63 and 64:
Grande 2005 PER (Continued) Allocat
Page 65 and 66:
Guthmann 2004 AGO (Continued) All d
Page 67 and 68:
Hasugian 2005 IDN Methods Trial des
Page 69 and 70:
Hutagalung 2002 THA (Continued) 5.
Page 71 and 72:
Janssens 2003 KHM (Continued) Free
Page 73 and 74:
Karema 2004 RWA (Continued) Interve
Page 75 and 76:
Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78:
Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80:
Koram 2003 GHA (Continued) Adequate
Page 81 and 82:
Martensson 2003 TZA Methods Trial d
Page 83 and 84:
Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86:
Menard 2006 MDG Methods Trial desig
Page 87 and 88:
Mens 2007 KEN (Continued) Risk of b
Page 89 and 90:
Mutabingwa 2004 TZA (Continued) •
Page 91 and 92:
Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94:
Sagara 2005b MLI (Continued) • 25
Page 95 and 96:
Smithuis 2004 MMR (Continued) Risk
Page 97 and 98:
Stohrer 2003 LAO Methods Trial desi
Page 99 and 100:
Swarthout 2004 ZAR (Continued) Note
Page 101 and 102:
Tran 2002 VNM Methods Trial design:
Page 103 and 104:
Van den Broek 2003a BGD (Continued)
Page 105 and 106:
Van Vugt 1998 THA Methods Trial des
Page 107 and 108:
Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110:
Yeka 2007 UGA (Continued) Free of o
Page 111 and 112:
Zongo 2007 BFA (Continued) Novartis
Page 113 and 114:
(Continued) Fofana 2005 Conference
Page 115 and 116:
D A T A A N D A N A L Y S E S Compa
Page 117 and 118:
2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120:
Comparison 5. Dihydroartemisinin-pi
Page 121 and 122:
Comparison 8. Artesunate plus meflo
Page 123 and 124:
Comparison 10. Artemether-lumefantr
Page 125 and 126:
Comparison 12. Artesunate plus amod
Page 127 and 128:
5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130:
Comparison 21. How does Artesunate
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
(... Continued) Study or subgroup D
Page 139 and 140:
Analysis 1.12. Comparison 1 Dihydro
Page 141 and 142:
(... Continued) Study or subgroup D
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
(... Continued) Study or subgroup A
Page 165 and 166:
Analysis 6.6. Comparison 6 Artesuna
Page 167 and 168:
Analysis 6.8. Comparison 6 Artesuna
Page 169 and 170: Analysis 7.2. Comparison 7 Artesuna
Page 171 and 172: Analysis 8.2. Comparison 8 Artesuna
Page 173 and 174: Analysis 9.2. Comparison 9 Artemeth
Page 175 and 176: (... Continued) Study or subgroup A
Page 177 and 178: Analysis 9.8. Comparison 9 Artemeth
Page 183 and 184: Analysis 10.2. Comparison 10 Arteme
Page 197 and 198: Analysis 12.2. Comparison 12 Artesu
Page 207 and 208: Analysis 14.2. Comparison 14 Dihydr
Page 217 and 218: (... Continued) Study or subgroup D
Page 219: Analysis 20.1. Comparison 20 How do
Page 223 and 224: (Continued) 2. How does artesunate
Page 225 and 226: (Continued) Sensitivity analysis 1
Page 227 and 228: (Continued) Smithuis 2004 MMR (652
Page 229 and 230: Dihydroartemisinin-piperaquine vs A
Page 231 and 232: (Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234: Artesunate plus mefloquine vs Amodi
Page 235 and 236: (Continued) Faye 2003 SEN (509 part
Page 237 and 238: Artemether-lumefantrine vs Artesuna
Page 239 and 240: (Continued) Zongo 2005 BFA (521 par
Page 241 and 242: (Continued) Faye 2003 SEN (521 part
Page 243 and 244: PCR = polymerase chain reaction PCV
Page 245 and 246: (Continued) Proportion with anaemia
Page 247 and 248: (Continued) Vivax efficacy: P. viva
Page 249 and 250: (Continued) Efficacy: Total Failure
Page 251 and 252: (Continued) Outcomes Illustrative c
Page 255 and 256: (Continued) GRADE Working Group gra
Page 257 and 258: Footnotes 1 Data were also availabl
Page 259 and 260: 8 Very serious imprecision: There w
Page 263 and 264: (Continued) justed Vivax efficacy:
Page 265 and 266: (Continued) Harms: Serious adverse
Page 267 and 268: (Continued) Harms: Early vomiting -
Page 269 and 270: 1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?